CRX, slightly below its current trading price.Pacira BioSciences, Inc. (NASDAQCRX) is a pharmaceutical company known for its focus on non-opioid pain management and regenerative health solutions. The company is a key player in the pharmaceutical industry, competing with other firms that develop pain management therapies. On January 30, 2025, Les Sulewski from Truist Financial set a price target of $25 for PCRX, while the stock was trading at $26.03. A class action lawsuit has been filed against Pacira BioSciences, alleging securities fraud. The lawsuit covers the period from August 2, 2023, to August 8, 2024, and seeks to recover losses for affected investors. The complaint points to a press release issued by Pacira on August 9, 2024, regarding a lawsuit outcome against eVenus for patent infringement, which highlighted issues with U.S. Patent No. 11,033,495.
Despite the legal challenges, PCRX is currently priced at $26.03, reflecting a 1.09% increase or $0.28. The stock has shown volatility, with a trading range between $25.39 and $26.73 during the day. Over the past year, PCRX has experienced significant fluctuations, reaching a high of $34.01 and a low of $11.16, indicating a volatile market environment.
Pacira BioSciences has a market capitalization of approximately $1.2 billion, reflecting its size and presence in the pharmaceutical sector. The trading volume for PCRX today is 961,781 shares, suggesting active investor interest despite the ongoing legal issues. Investors affected by the alleged securities fraud are encouraged to contact Joseph E. Levi, Esq., or the team at Levi & Korsinsky for more information on potential recovery under federal securities laws.
Read More